Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $27.65 and traded as low as $18.98. Capricor Therapeutics shares last traded at $19.79, with a volume of 2,254,084 shares traded.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Roth Capital restated a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $53.67.

Capricor Therapeutics Price Performance

The business’s 50-day moving average price is $25.67 and its two-hundred day moving average price is $27.58. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -8.55 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the transaction, the chief financial officer owned 8,223 shares of the company’s stock, valued at $260,669.10. This represents a 75.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 50,000 shares of company stock worth $1,551,658. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors have recently added to or reduced their stakes in CAPR. Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares during the last quarter. ACT Capital Management LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter worth approximately $43,000. KBC Group NV acquired a new stake in shares of Capricor Therapeutics in the first quarter worth approximately $44,000. Tower Research Capital LLC TRC grew its holdings in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC purchased a new stake in Capricor Therapeutics in the third quarter valued at approximately $92,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.